OakChart

Adma Biologics Inc

ADMAHealthcare·Biotechnology·USA·Mid·NASD·Nov 13 • 7:02 AM ET

13.39+0.15 (1.13%)
2026-11-13 13:21 CET
Market cap
$2.97B
Revenue, TTM
519.15 USD m
Net income, TTM
182.41 USD m
Free cash flow, TTM
132.91 USD m
EPS diluted, TTM
0.78
Price / earnings
17.24
Compare

Price

ADMA against its 20, 50 and 200-day averages
Terms2050200BeatEarnings
Patternshover a marker to name it
RS 15Sales 155Price1551628.0010.0012.0014.0016.007.5M15.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ADMAclose 13.3920-day 11.7750-day 10.57200-day 10.7213.3952w low 7.2152-week range, not 6 months

34.5% under the 52-week high of 20.46 on 12 Dec 2025. 52-week low 7.21 on 26 Mar 2026. Last 15 sessions, 34.3% high to low

Volume 0.00× normal · the line is the 50-bar volume average

Setup. RS line 15
CANSLIM 3 of 6 — fails: EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; RSI (14): Not Overbought (<60)
Minervini 1 of 4 — fails: 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 3 of 5 — fails: Performance: Week +10%; Relative Volume: Over 1.5
Leaders 3 of 5 — fails: Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 2 of 4 — fails: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 4 of 5 — fails: Debt/Equity: Low (<0.1)
Value 1 of 4 — fails: P/E: Under 15; P/B: Under 2; Debt/Equity: Low (<0.1)
Income 2 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%
Small Cap 2 of 4 — fails: Float: Under 100M; Performance: Year +50%
Accumulation 2 of 4 — fails: Institutional Transactions: Over +10%; Performance: Year Up
Relative Strength 2 of 3 — fails: Performance: Year +100%

Profile

ADMA
52-week range, 47% of the way up
7.2120.46

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

IndexRUT
Employees647
IPOOct 17, 2013
Beta0.65
ATR, 14d0.61
Rel volume0.00
Short float8.50%
Insider own4.30%
Inst own87.89%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap$2.97B
Enterprise Value3.05B
Income182.41M
Sales519.15M
Book / share1.97
Cash / share0.56
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees647
IPOOct 17, 2013

Ratios

Price / earnings17.24
Forward price / earnings15.09
Price / earnings / growth0.78
Price / sales5.72
Price / book6.80
Price / cash23.85
Price / free cash flow22.35
Value / cash profit12.67
Value / sales5.87
Quick Ratio3.25
Current Ratio6.04
Debt / equity0.46
Long-term debt / equity0.45
Options and shortYes / Yes

Earnings

Earnings / share0.78
Earnings next year0.89
Earnings next quarter0.24
Earnings this year24.48%
Earnings next year8.56%
Earnings growth, 5 years19.38%
Past earnings growth- -
Past sales growth49.05% 64.60%
Earnings vs last year-10.51%
Sales vs last year6.26%
Earnings vs last quarter48.35%
Sales vs last quarter5.12%
EarningsNov 04 AMC
Surprise14.49% 2.17%

Ownership

Insiders own4.30%
Insider trades-1.33%
Institutions own87.89%
Institution trades-3.87%
Return on assets28.04%
Return on equity41.95%
Return on capital28.69%
Gross Margin68.48%
Operating margin44.93%
Profit Margin35.14%
20-day average13.72%
50-day average26.69%
200-day average24.86%

Technical

Shares out222.79M
Shares floating212.30M
Short / float8.50%
Short ratio5.83
Short interest18.04M
52-week high20.46 -34.5%
52-week low7.21 +85.7%
Volatility4.46% 4.88%
Average range0.61
Strength index69.32
Market sensitivity0.65
Relative volume0.00
Avg Volume3.10M
Volume204

Performance

Perf Week5.18%
Perf Month24.79%
Perf Quarter43.36%
Perf Half Y61.91%
Perf YTD-26.59%
Perf Year-14.71%
Perf 3Y258.02%
Perf 5Y706.63%
Perf 10Y109.87%
Recommendation1.75
Target Price18.00
Prev Close13.24
Price13.39
Change %1.13%

Analyst ratings

latest 10 of 18
DateActionAnalystRating changeTargetImplied
Jun 10, 2026ResumedRaymond JamesOutperform$21+56.8%
Apr 21, 2026InitiatedCanaccord GenuityBuy$21+56.8%
Mar 26, 2026DowngradeCantor FitzgeraldOverweight → Neutral
Jul 19, 2023ResumedRaymond JamesStrong Buy$5-62.7%
Oct 13, 2022InitiatedMizuhoBuy$5-62.7%
Nov 11, 2021UpgradeRaymond JamesOutperform → Strong Buy$5-62.7%
Nov 09, 2021InitiatedCantor FitzgeraldOverweight$4.50-66.4%
Jun 04, 2019InitiatedJefferiesBuy$8-40.3%
Apr 15, 2019ReiteratedH.C. WainwrightBuy$10 → $13-2.9%
Feb 07, 2019ResumedH.C. WainwrightBuy$10-25.3%

Peers

Mkt cap
TickerCompanyMkt cap
GRFSGrifols SA ADR2.27B
KMDAKamada Ltd474.59M
HRMYHarmony Biosciences Holdings Inc2.01B
VCELVericel Corp2.93B
MIRMMirum Pharmaceuticals Inc6.09B
TAKTakeda Pharmaceutical Co ADR68.75B
AUPHAurinia Pharmaceuticals Inc2.16B
PTCTPTC Therapeutics Inc5.29B
EBSEmergent Biosolutions Inc300.27M
HAEHaemonetics Corp5.59B

Insider trading

latest 14 of 22
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Grossman Adam SPresident and CEONov 05 '26Option Exercise5.40105,000567,0002,217,777Nov 05 09:05 PM
Grossman Adam SPresident and CEONov 05 '26Sale12.00147,0001,764,0002,070,777Nov 05 09:05 PM
Grossman Adam S.DirectorNov 05 '26Proposed Sale10.48189,0001,980,720Nov 05 09:00 PM
Grossman Jerrold BDirectorMay 27 '26Buy7.916,40050,624520,284May 28 04:05 PM
Grossman Jerrold BDirectorMay 12 '26Buy8.0112,500100,125513,884May 14 07:00 AM
Grossman Jerrold BDirectorMay 11 '26Buy8.0112,500100,125501,384May 12 05:22 PM
Guiheen Lawrence P.DirectorMar 13 '26Option Exercise3.6630,000109,800135,520Mar 17 09:00 PM
Grossman Adam SPresident and CEOMar 16 '26Option Exercise5.4015,00081,0002,133,777Mar 17 09:00 PM
Grossman Adam SPresident and CEOMar 16 '26Sale15.1621,000318,3602,112,777Mar 17 09:00 PM
Tade Brad L.Former OfficerMar 10 '26Proposed Sale15.8150,026790,911Mar 10 09:45 PM
Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceMar 09 '26Option Exercise3.2010,09632,331476,696Mar 10 09:00 PM
Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceMar 09 '26Sale15.6310,096157,800466,600Mar 10 09:00 PM
Kestenberg-Messina Kaitlin M.OfficerMar 09 '26Proposed Sale15.3910,096155,377Mar 09 09:00 PM
ELMS STEVEDirectorMar 05 '26Buy15.677,000109,6902,038,730Mar 09 09:14 AM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 107.13B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.07B
IWMiShares Russell 2000 Index FundAUM: 77.86B
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
XBIState Street SPDR S&P Biotech ETFAUM: 10.59B
IWOiShares Russell 2000 Growth ETFAUM: 14.25B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.19B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.52B
VXFVanguard Extended Market Index ETFAUM: 30.79B
VBVanguard Morningstar Small-Cap ETFAUM: 80.23B

News

latest 14 of 200
  • ADMA Biologics Beats On ASCENIV Acceleration And Margin Strength, But Floor-Level Revenue Guidance And Slower Cash Conversion Temper The Quarter (Earnings Whispers) -5.67% +26.05%
  • Adma Biologics: Q3 Earnings Snapshot (Associated Press)
  • ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • ADMA Needs Ascentiv's Summer Surge To Lift Revenue Off The Low End Of Guidance (Earnings Whispers)
  • ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire)
  • ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process (GlobeNewswire)
  • ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA (PR Newswire)
  • ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ... (GuruFocus.com) +8.64%
  • Adma Biologics: Q2 Earnings Snapshot (Associated Press)
  • ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Earnings To Watch: ADMA Biologics Inc (ADMA) Q2 2026 -- GF Value Sees 149% Upside (GuruFocus.com)
  • ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026 (GlobeNewswire)
  • ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA (PR Newswire)
  • ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA (PR Newswire)

Quarterly earnings

2026Q3 EPS 0.225 beat 0.197, from 0.160 a year earlier. Sales 141.1 beat 138.11, from 134.22 a year earlier
EPS
0.22502024Q4 EPS 0.141 against 0.15024Q42025Q1 EPS 0.136 against 0.15325Q12025Q2 EPS 0.147 against 0.13725Q22025Q3 EPS 0.160 against 0.14625Q32025Q4 EPS 0.213 against 0.18525Q42026Q1 EPS 0.171 against 0.19326Q12026Q2 EPS 0.165 against 0.16326Q22026Q3 EPS 0.225 against 0.19726Q3
Sales, USD millions
141.102024Q4 sales 117.55 against 112.7724Q42025Q1 sales 114.8 against 116.4125Q12025Q2 sales 121.98 against 121.7725Q22025Q3 sales 134.22 against 131.925Q32025Q4 sales 139.16 against 139.625Q42026Q1 sales 114.49 against 139.9826Q12026Q2 sales 124.4 against 125.3426Q22026Q3 sales 141.1 against 138.1126Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026Q3ended 2026-09-302026-11-04 16:300.2250.1970.220141.1138.11EPS +14.5% · sales +2.2%vs 2025Q3, year-ago quarter · EPS +40.7% · sales +5.1%3Open +14.60% vs SPY -0.17%. Close +26.05% vs SPY -4.41%
2026Q2ended 2026-06-302026-08-05 16:300.1650.1630.164124.4125.34EPS +1.0% · sales -0.8%vs 2025Q2, year-ago quarter · EPS +11.9% · sales +2.0%3Open +4.75% vs SPY +0.05%. Close +8.64% vs SPY -0.16%
2026Q1ended 2026-03-312026-05-06 16:300.1710.1930.189114.49139.98EPS -11.7% · sales -18.2%vs 2025Q1, year-ago quarter · EPS +25.3% · sales -0.3%3Open -25.35% vs SPY +0.17%. Close -15.97% vs SPY -0.31%
2025Q4ended 2025-12-312026-02-25 16:300.2130.1850.203139.16139.6EPS +15.2% · sales -0.3%vs 2024Q4, year-ago quarter · EPS +51.3% · sales +18.4%2Open +3.64% vs SPY +0.02%. Close -3.19% vs SPY -0.56%
2025Q3ended 2025-09-302025-11-05 16:300.1600.1460.149134.22131.9EPS +9.4% · sales +1.8%vs 2024Q3, year-ago quarter · EPS -1.8% · sales +12.0%3Open -3.12% vs SPY -0.16%. Close -8.72% vs SPY -1.07%
2025Q2ended 2025-06-302025-08-06 16:300.1470.1370.138121.98121.77EPS +7.8% · sales +0.2%vs 2024Q2, year-ago quarter · EPS +3.9% · sales +13.8%3Open -14.51% vs SPY +0.55%. Close -9.65% vs SPY -0.08%
2025Q1ended 2025-03-312025-05-07 16:300.1360.1530.110114.8116.41EPS -11.2% · sales -1.4%vs 2024Q1, year-ago quarter · EPS +52.7% · sales +40.2%3Open -3.73% vs SPY +0.73%. Close -10.21% vs SPY +0.70%
2024Q4ended 2024-12-312025-03-03 16:300.1410.1500.455117.55112.77EPS -6.1% · sales +4.2%vs 2023Q4, year-ago quarter · EPS -276.1% · sales +59.1%3Open -5.91% vs SPY -0.70%. Close +7.45% vs SPY -1.18%
2024Q3ended 2024-09-302024-11-07 16:300.1630.1300.147119.84105.81EPS +25.4% · sales +13.3%vs 2023Q3, year-ago quarter · EPS +1530.0% · sales +78.1%4Open +5.27% vs SPY +0.09%. Close +14.71% vs SPY +0.43%
2024Q2ended 2024-06-302024-08-08 16:300.1420.0800.132107.1986.44EPS +77.3% · sales +24.0%vs 2023Q2, year-ago quarter · EPS -905.7% · sales +78.4%4Open +23.87% vs SPY -0.16%. Close +30.93% vs SPY +0.44%
2024Q1ended 2024-03-312024-05-09 16:300.0890.0550.07581.8877.28EPS +62.0% · sales +6.0%vs 2023Q1, year-ago quarter · EPS -397.0% · sales +43.9%4Open +18.33% vs SPY +0.32%. Close +27.13% vs SPY +0.13%
2023Q4ended 2023-12-312024-02-28 16:30-0.0800.025-0.07873.9072.13EPS -420.0% · sales +2.5%vs 2022Q4, year-ago quarter · EPS +33.3% · sales +47.9%4Open 0.00% vs SPY +0.36%. Close -0.37% vs SPY +0.36%
2023Q3ended 2023-09-302023-11-08 16:300.010-0.0080.01167.3062.13EPS -233.3% · sales +8.3%vs 2022Q3, year-ago quarter · EPS -112.5% · sales +63.8%4-
2023Q2ended 2023-06-302023-08-09 16:30-0.018-0.025-0.02960.1055.50EPS -29.6% · sales +8.3%vs 2022Q2, year-ago quarter · EPS -74.9% · sales +77.3%4-
2023Q1ended 2023-03-312023-05-10 16:30-0.030-0.043-0.03156.9151.26EPS -29.4% · sales +11.0%vs 2022Q1, year-ago quarter · EPS -76.9% · sales +95.6%4-
2022Q4ended 2022-12-312023-03-23 16:30-0.060-0.070-0.06049.9846.35EPS -14.3% · sales +7.8%vs 2021Q4, year-ago quarter · EPS -33.3% · sales +89.4%4-

Annual earnings

2025FY EPS 0.657 beat 0.585, from 0.488 a year earlier. Sales 510.17 missed 510.6, from 426.45 a year earlier
EPS
0.6570-1.4502018FY EPS -1.450 against -1.39320182019FY EPS -0.890 against -0.88820192020FY EPS -0.880 against -0.84320202021FY EPS -0.510 against -0.51320212022FY EPS -0.330 against -0.33020222023FY EPS -0.130 against -0.02020232024FY EPS 0.488 against 0.51320242025FY EPS 0.657 against 0.5852025
Sales, USD millions
510.602018FY sales 16.99 against 18.1320182019FY sales 29.35 against 26.7420192020FY sales 42.22 against 41.0720202021FY sales 80.94 against 76.2420212022FY sales 154.08 against 151.4820222023FY sales 258.22 against 256.4520232024FY sales 426.45 against 421.6720242025FY sales 510.17 against 510.62025

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2030FYestimate-1.628--894.948.23
2029FYestimate-1.360--793.049.85
2028FYestimate-1.118--698.3511.98
2027FYestimate-0.888--612.5615.09
2026FYestimate-0.818--534.7916.38
2025FY0.6570.5850.600510.17510.627.77
2024FY0.4880.5130.812426.45421.6735.17
2023FY-0.130-0.020-0.126258.22256.45-
2022FY-0.330-0.330-0.333154.08151.48-
2021FY-0.510-0.513-0.51380.9476.24-
2020FY-0.880-0.843-0.87942.2241.07-
2019FY-0.890-0.888-0.88829.3526.74-
2018FY-1.450-1.393-1.45516.9918.13-
2017FY-1.910-1.915-1.91022.7618.86-
2016FY-1.610-1.595-1.61010.668.60-
2015FY-1.730-1.716-1.7307.186.58-
2014FY-1.810-1.808-1.8105.925.80-
2013FY-2.212-2.287-2.3803.073.22-

Quarterly results

2026Q3 revenue 141.1, from 134.22 a year earlier. Operating margin 48.0%, from 38.0% a year earlier
Revenue, USD millions
141.102024Q4 revenue 117.5524Q42025Q1 revenue 114.825Q12025Q2 revenue 121.9825Q22025Q3 revenue 134.2225Q32025Q4 revenue 139.1625Q42026Q1 revenue 114.4926Q12026Q2 revenue 124.3926Q22026Q3 revenue 141.126Q3
Operating margin
48.002024Q4 operating margin 32.6%24Q42025Q1 operating margin 30.4%25Q12025Q2 operating margin 35.1%25Q22025Q3 operating margin 38.0%25Q32025Q4 operating margin 45.1%25Q42026Q1 operating margin 43.9%26Q12026Q2 operating margin 42.2%26Q22026Q3 operating margin 48.0%26Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2026FY E 0.82 per share.
PeriodTypeScaleDateMeanvs prior date
2026FYEper share2026-11-050.82+2.6%
2026Q4Eper share2026-11-050.24-1.4%
2026FYRper share2026-11-050.82+2.9%
2026Q4Rper share2026-11-050.24-1.3%
2026FYS-2026-11-05534.79-0.1%
2026Q4S-2026-11-05154.79-2.3%
2026Q3Eper share2026-10-200.200.0%
2026Q3Rper share2026-10-200.190.0%
2026Q3S-2026-10-20138.110.0%
2026Q2Eper share2026-07-310.16-0.9%
2026Q2Rper share2026-07-310.16-1.5%
2026Q2S-2026-07-21125.340.0%
2026Q1Eper share2026-05-040.19-0.8%
2026Q1S-2026-05-04139.980.0%
2026Q1Rper share2026-04-100.19-3.4%
2025FYEper share2026-01-200.590.0%
2025Q4Eper share2026-01-200.190.0%
2025FYRper share2026-01-200.590.0%
2025Q4Rper share2026-01-200.190.0%
2025FYS-2026-01-20510.60.0%
2025Q4S-2026-01-20139.60.0%
2025Q3Rper share2025-10-240.15+0.7%
2025Q3Eper share2025-10-210.150.0%
2025Q3S-2025-10-21130.520.0%
2025Q2Eper share2025-07-220.140.0%
2025Q2Rper share2025-07-220.140.0%
2025Q2S-2025-07-22122.67+0.7%
2025Q1Eper share2025-04-280.15+0.9%
2025Q1Rper share2025-04-280.15+0.9%
2025Q1S-2025-04-25116.41+0.0%
2024FYS-2025-02-05421.67-0.2%
2024FYEper share2025-02-040.51+1.3%
2024Q4Eper share2025-01-220.150.0%
2024FYRper share2025-01-220.510.0%
2024Q4Rper share2025-01-220.150.0%
2024Q4S-2025-01-22112.770.0%
2024Q3S-2024-10-31105.81-0.1%
2024Q3Eper share2024-10-230.130.0%
2024Q3Rper share2024-10-230.130.0%
2024Q2Eper share2024-07-240.080.0%
2024Q2Rper share2024-07-240.080.0%
2024Q2Sper share2024-07-2486.440.0%
2024Q1Sper share2024-03-2377.280.0%
2024Q1Eper share2024-02-290.06+46.7%
2024Q1Rper share2024-02-290.06+54.5%
2023FYEper share2024-01-23-0.020.0%
2023FYRper share2024-01-23-0.020.0%
2023FYS-2024-01-23256.450.0%

Estimate history

Annual
Metric201720182019202020212022202320242025TTMMRQ
EPS per share-1.91-1.455-0.888-0.879-0.513-0.333-0.1260.8120.60.7765-
Sales USD millions2317294281154258426510519-
Shares million shares454659105196222226237238-223
Quarterly
MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS per share0.1470.4550.110.1380.1490.2030.1890.1640.221
Sales USD millions120118115122134139114124141
Shares million shares236237239239238238232225223

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Total Revenue519.15510.17+19.6%426.45+65.2%258.21+67.6%154.08+90.4%80.94+91.7%42.22+43.9%29.35+72.7%16.99
Cost of Goods Sold Incl. D&A163.61217.55+4.9%207.29+21.9%170.00+42.2%119.53+48.5%80.48+29.8%62.01+53.7%40.35-6.3%43.04
Gross Profit355.54292.62+33.5%219.16+148.4%88.22+155.3%34.55+7410.9%0.46-19.79-11.00-26.05
Selling, General and Administrative Excl. Other122.29101.18+26.2%80.18+20.4%66.59-10.2%74.13+25.5%59.07+30.9%45.13+48.4%30.42+0.3%30.33
Research and Development14.484.76+163.0%1.81-45.2%3.30-13.8%3.83-1.5%3.89-34.2%5.91+152.6%2.34-40.5%3.93
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income233.25191.44+37.7%138.98+542.5%21.63-39.58-58.61-64.91-41.42-56.39
Interest Expense10.587.11-49.0%13.93-44.3%25.03+29.8%19.28+47.6%13.06+8.9%11.99+33.4%8.99+62.9%5.52
Unusual Expense0.003.34+169.4%1.24-95.3%26.17+292.4%6.670.00-0.99-109.9%9.96+155.4%3.90
Net Income Before Taxes234.56182.66+45.3%125.71-28.24-66.12-71.89-75.75-48.28-65.74
Income Taxes52.1535.73-71.960.00-0.21-0.240.000.000.00
Consolidated Net Income182.41146.93-25.7%197.67-28.24-65.90-71.65-75.75-48.28-65.74
Net Income From Continuing Operations182.41146.93-25.7%197.67-28.24-65.90-71.65-75.75-48.28-65.74
Net Income182.41146.93-25.7%197.67-28.24-65.90-71.65-75.75-48.28-65.74
EPS (Recurring) per share0.810.61-25.6%0.82-0.04-0.31-0.51-0.89-0.76-1.39
EPS (Basic, Before Extraordinaries) per share0.790.62-27.1%0.85-0.13-0.33-0.51-0.88-0.89-1.45
EPS (Diluted) per share0.780.60-25.9%0.81-0.13-0.33-0.51-0.88-0.89-1.45
EBITDA240.70199.54+35.7%147.03+390.8%29.96-32.46-53.12-60.97-38.17-52.94
Non-Operating Income (Expense)11.901.66-12.6%1.90+42.9%1.33-0.59-0.22-237.5%0.16-98.7%12.10+17185.7%0.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense19.0115.82+47.0%10.76+73.8%6.19+18.8%5.21+49.3%3.49+22.0%2.86+7.9%2.65+19.4%2.22
Price To Earnings Ratio ratio statement ratio, not the snapshot17.0517.0562.07------
Price To Sales Ratio ratio4.368.769.793.924.982.433.987.416.36
Gross Margin %68.4857.3651.3934.1622.420.57-46.87-37.48-153.39
Operating Margin %44.9337.5332.598.38-25.69-72.41-153.75-141.14-331.99
Net Margin %35.1428.8046.35-10.94-42.77-88.52-179.41-164.50-387.06
Shares Outstanding million shares222.79237.87+0.5%236.62+4.7%226.06+1.9%221.82+13.3%195.81+86.7%104.90+76.8%59.32+28.0%46.35
Market Capitalization2,937.352,937.35-27.5%4,054.09+296.9%1,021.38+20.9%844.89+206.0%276.10+49.8%184.37-22.3%237.27+114.2%110.78

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Total Revenue141.10+5.1%124.39+2.0%114.49-0.3%139.16+18.4%134.22+12.0%121.98+13.8%114.80+40.2%117.55+59.1%
Cost of Goods Sold Incl. D&A41.24-29.7%38.17-30.3%33.80-37.1%50.40-7.1%58.64-2.6%54.79+9.8%53.73+25.1%54.24+26.1%
Gross Profit99.86+32.1%86.22+28.3%80.69+32.1%88.77+40.2%75.59+26.8%67.19+17.2%61.07+57.0%63.31+104.9%
Selling, General and Administrative Excl. Other32.10+30.6%33.78+38.4%30.40+16.1%26.01+4.1%24.58+23.0%24.40+34.7%26.19+53.2%24.98+49.9%
Research and Development4.49+193.5%6.01+483.5%2.60+213.3%1.38+253.8%1.53+273.2%1.03+83.9%0.83+84.4%0.39-13.3%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income67.76+32.8%52.45+22.5%50.29+44.2%62.75+63.8%51.01+28.7%42.80+9.2%34.88+59.9%38.32+169.3%
Interest Expense3.43+104.2%3.42+86.9%2.10+6.1%1.63-43.4%1.68-52.0%1.83-51.6%1.98-47.5%2.88-53.6%
Unusual Expense0.00-100.0%0.00-100.0%0.000.00-100.0%2.181.160.001.24-95.3%
Net Income Before Taxes65.60+38.0%50.24+25.3%57.13+70.8%61.59+77.4%47.52+29.3%40.10+11.9%33.45+81.8%34.71
Income Taxes15.72+41.7%12.41+111.1%11.80+80.2%12.2211.09+1220.2%5.88+55.1%6.55+1010.2%-77.18
Consolidated Net Income49.88+36.9%37.82+10.5%45.33+68.5%49.38-55.9%36.43+1.4%34.22+6.7%26.90+51.0%111.90
Net Income From Continuing Operations49.88+36.9%37.82+10.5%45.33+68.5%49.38-55.9%36.43+1.4%34.22+6.7%26.90+51.0%111.90
Net Income49.88+36.9%37.82+10.5%45.33+68.5%49.38-55.9%36.43+1.4%34.22+6.7%26.90+51.0%111.90
EPS (Recurring) per share0.22+37.5%0.16+14.3%0.19+72.7%0.20-56.5%0.16+6.7%0.14+7.7%0.11+37.5%0.46
EPS (Basic, Before Extraordinaries) per share0.22+46.7%0.17+21.4%0.19+72.7%0.21-55.3%0.150.0%0.140.0%0.11+37.5%0.47
EPS (Diluted) per share0.22+46.7%0.16+14.3%0.19+72.7%0.20-56.5%0.150.0%0.14+7.7%0.11+37.5%0.46
EBITDA69.55+31.1%54.23+20.9%52.13+41.5%64.80+60.9%53.04+27.6%44.86+8.8%36.85+54.0%40.27+146.5%
Non-Operating Income (Expense)1.28+265.7%1.22+320.7%8.93+1553.7%0.47-7.8%0.35-42.6%0.29-32.6%0.54+54.3%0.510.0%
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.90+22.8%4.85+23.7%5.00+37.0%4.26-0.7%3.99+59.0%3.92+73.5%3.65+116.0%4.29+210.9%
Price To Earnings Ratio ratio statement ratio, not the snapshot17.0512.3515.0421.4217.2621.5724.5162.07
Price To Sales Ratio ratio4.363.764.248.727.349.5510.579.89
Gross Margin %70.7769.3170.4863.7856.3155.0953.2053.86
Operating Margin %48.0242.1643.9345.0938.0135.0830.3832.60
Net Margin %35.3530.4039.5935.4827.1428.0523.4495.19
Shares Outstanding million shares222.79-6.5%225.36-5.9%232.29-2.6%237.87+0.5%238.33+0.8%239.38+2.7%238.53+2.9%236.62+4.7%
Market Capitalization2,937.35-16.0%1,939.94-55.4%2,145.81-54.5%4,341.08+7.1%3,498.33-24.9%4,347.35+67.7%4,714.28+213.0%4,054.09+296.9%

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/20182017FY12/31/2017
Cash & Short Term Investments87.63-15.0%103.15+100.9%51.35-40.6%86.52+69.3%51.09-8.6%55.92+109.0%26.75+17.6%22.75-49.0%44.61
Short Term Receivables158.43+216.9%50.00+82.3%27.42+76.8%15.51-45.7%28.58+115.9%13.24+281.6%3.47+149.6%1.39-64.2%3.88
Inventories206.47+21.3%170.24-1.5%172.91+5.9%163.28+30.9%124.72+53.0%81.54+53.7%53.06+185.0%18.62+47.4%12.63
Other Current Assets13.99+74.2%8.03+50.7%5.33+4.5%5.10+17.5%4.34+42.3%3.05+20.6%2.53+42.9%1.77-13.7%2.05
Total Current Assets466.51+40.8%331.41+28.9%257.01-5.0%270.40+29.5%208.73+35.8%153.74+79.1%85.82+92.7%44.53-29.5%63.17
Net Property, Plant & Equipment71.71+13.2%63.34-0.2%63.47-7.7%68.75+18.1%58.20+26.9%45.85+38.4%33.14+10.0%30.12-1.1%30.47
Total Investments and Advances0.000.000.000.000.000.000.00-100.0%4.000.0%4.00
Intangible Assets4.16+4.3%3.99-1.0%4.03-11.2%4.54-13.7%5.26-11.9%5.97-10.8%6.69-11.2%7.53-10.1%8.38
Deferred Tax Assets82.37-12.4%93.98-------
Other Assets8.60+51.9%5.66+21.2%4.67-2.1%4.77+17.2%4.07+92.9%2.11+46.5%1.44-46.7%2.70+34.3%2.01
Total Assets633.35+27.1%498.38+51.4%329.18-5.5%348.46+26.1%276.25+33.0%207.67+63.4%127.09+43.0%88.88-17.7%108.02
Short Term Debt Incl. Current Port. of LT Debt3.91+220.5%1.22+17.3%1.04+14.3%0.91+54.2%0.59+59.5%0.37+60.9%0.23+666.7%0.030.00
Accounts Payable22.52+11.4%20.22+29.1%15.66+18.4%13.23+6.4%12.43+12.3%11.07+20.7%9.17+55.4%5.90-0.3%5.92
Income Tax Payable8.62+147.7%3.48-------
Other Current Liabilities34.50+12.7%30.62-7.5%33.10+31.7%25.13+44.8%17.36+104.0%8.51+84.2%4.62+25.2%3.69+4.8%3.52
Total Current Liabilities69.54+25.2%55.54+11.5%49.81+26.8%39.27+29.3%30.38+52.3%19.95+42.2%14.03+45.7%9.63+2.0%9.44
Long Term Debt75.98-6.1%80.90-42.4%140.37-8.6%153.54+50.0%102.33+5.2%97.30+15.1%84.50+91.2%44.19+2.8%42.97
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities9.11-6.1%9.70-------
Other Liabilities1.41-56.2%3.22-15.3%3.80+3.3%3.68+55.3%2.37+9.2%2.17-8.4%2.37-84.5%15.29+0.1%15.28
Total Liabilities156.03+4.5%149.36-23.0%193.98-1.3%196.49+45.5%135.08+13.1%119.42+18.4%100.90+46.0%69.11+2.1%67.69
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity477.32+36.8%349.02+158.1%135.21-11.0%151.97+7.7%141.17+60.0%88.25+237.0%26.19+32.5%19.77-51.0%40.33
Total Shareholders Equity477.32+36.8%349.02+158.1%135.21-11.0%151.97+7.7%141.17+60.0%88.25+237.0%26.19+32.5%19.77-51.0%40.33
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity477.32+36.8%349.02+158.1%135.21-11.0%151.97+7.7%141.17+60.0%88.25+237.0%26.19+32.5%19.77-51.0%40.33
Total Liabilities & Stockholders Equity633.35+27.1%498.38+51.4%329.18-5.5%348.46+26.1%276.25+33.0%207.67+63.4%127.09+43.0%88.88-17.7%108.02
Book Value Per Share per share2.01+35.8%1.48+146.7%0.60-13.0%0.69-4.2%0.72-14.3%0.84+90.9%0.44+2.3%0.43-51.7%0.89
Tangible Book Value Per Share per share1.99+36.3%1.46+151.7%0.58-12.1%0.66-4.3%0.69-11.5%0.78+136.4%0.33+26.9%0.26-63.4%0.71
Full-Time Employees people647-5.5%685+9.8%624+1.1%617+17.1%527+29.5%407+29.6%314-1.3%318+7.8%295
Price to Book Ratio ratio6.7317.486.747.611.962.329.065.606.37
Return on Assets %25.9747.77-8.33-21.10-29.61-45.25-44.71-66.78-66.45
Return on Equity %35.5681.65-19.67-44.96-62.46-132.38-210.08-218.77-243.95
Return on Invested Capital %26.5645.98-10.25-21.57-29.42-40.82-43.61-102.78-52.53
Quick Ratio ratio3.742.901.692.732.773.622.342.695.35
Current Ratio ratio6.715.975.166.896.877.716.124.636.69

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Net Income182.41146.93-25.7%197.67-28.24-65.90-71.65-75.75-48.28-65.74
Depreciation7.468.10+0.7%8.04-3.5%8.33+17.2%7.11+29.3%5.50+39.6%3.94+20.9%3.26-5.5%3.45
Other Funds (Non Cash)16.7723.95+51.9%15.77-59.4%38.83+121.0%17.57+221.8%5.46+52.5%3.58+53.6%2.33-29.6%3.31
Funds from Operations210.38189.99+38.5%137.21+625.2%18.92-41.22-60.69-68.22-42.69-58.99
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-69.59-139.59-18.54-10.12-18.29-51.68-33.78-33.50-3.69
Cash from Operating Activities140.7950.40-57.5%118.67+1248.5%8.80-59.51-112.37-102.00-76.19-62.68
Capital Expenditures-8.20-22.89-8.57-4.98-13.91-13.51-12.73-3.81-2.10
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses6.001.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-2.20-21.89-8.57-4.98-13.91-13.51-12.72-3.81-2.10
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-188.14-28.96-486.6%7.49+580.9%1.10-98.3%64.82-46.5%121.14-7.7%131.21+170.7%48.47+12.8%42.96
Repurchase of Common Pref Stock-189.20-31.940.000.000.000.000.000.000.00
Sale of Common Pref Stock1.062.98-60.2%7.49+580.9%1.10-98.3%64.82-46.5%121.14-7.7%131.21+170.7%48.47+12.8%42.96
Proceedsfrom Stock Options0.000.000.000.00-100.0%64.65-46.6%121.14-7.7%131.20+171.1%48.40+12.7%42.94
Issuance or Reduction of Debt, Net123.67-3.17-60.83-38.68-182.4%46.93-0.03-100.2%12.69-59.8%31.53-0.04
Change in Long Term Debt123.67-3.17-60.83-38.68-182.4%46.93-0.03-100.2%12.69-59.8%31.53-0.04
Issuance of Long Term Debt124.99102.760.00-100.0%121.51-17.3%146.970.00-100.0%26.67-56.7%61.560.00
Reduction of Long Term Debt-1.31-105.94-60.83-160.19-100.04-0.03-13.98-30.03-0.04
Net Financing Active Other Cash Flow-10.96-11.89-4.97-1.42-2.90-0.060.000.000.00
Other Financing Activities Uses-10.96-11.89-4.97-1.42-2.90-0.060.000.000.00
Cash from Financing Activities-75.43-44.02-58.30-38.99-135.8%108.85-10.1%121.05-15.9%143.90+79.9%80.00+86.4%42.92
Net Change in Cash63.17-15.52-130.0%51.80-35.17-199.3%35.43-4.83-116.6%29.17-0.00-21.85
Free Cash Flow132.9127.82-74.8%110.45+2640.7%4.03-73.42-125.88-114.73-80.01-64.77
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow ratio17.04160.5637.79251.27-----
Deferred Taxes & Investment Tax Credit-11.02-84.280.000.000.000.000.000.00

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Cash & Short Term Investments124.56+102.9%136.02+50.7%138.15+92.9%87.63-15.0%61.38-29.2%90.28+2.3%71.62+58.0%103.15+100.9%
Short Term Receivables169.22+22.9%138.23+26.0%135.86+36.7%158.43+216.9%137.67+174.6%109.73+264.4%99.41+100.3%50.00+82.3%
Inventories266.12+35.3%239.31+25.0%222.10+29.0%206.47+21.3%196.67+14.5%191.46+6.5%172.19-3.1%170.24-1.5%
Other Current Assets15.97+130.4%14.64+81.0%15.06+75.3%13.99+74.2%6.93-27.4%8.09+46.6%8.59+129.7%8.03+50.7%
Total Current Assets575.86+43.0%528.20+32.2%511.17+45.3%466.51+40.8%402.65+26.5%399.56+31.6%351.81+27.3%331.41+28.9%
Net Property, Plant & Equipment72.64-7.8%72.81+9.6%71.41+8.6%71.71+13.2%78.78+25.9%66.46+4.7%65.73+1.6%63.34-0.2%
Total Investments and Advances0.000.000.000.000.000.000.000.00
Intangible Assets4.11+2.2%4.11+1.2%4.16+4.5%4.16+4.3%4.02+0.2%4.06+1.2%3.98+3.4%3.99-1.0%
Deferred Tax Assets70.69-5.0%69.97-11.7%69.97-13.5%82.37-12.4%74.4379.2380.8693.98
Other Assets9.18+4.3%9.13+0.8%8.47+3.4%8.60+51.9%8.80+51.2%9.06+73.6%8.19+39.0%5.66+21.2%
Total Assets732.49+28.8%684.21+22.5%665.18+30.3%633.35+27.1%568.69+45.6%558.38+48.3%510.57+45.5%498.38+51.4%
Short Term Debt Incl. Current Port. of LT Debt5.40+48.4%4.93+336.3%4.46+274.8%3.91+220.5%3.64+205.9%1.13-0.9%1.19+9.2%1.22+17.3%
Accounts Payable35.66+48.5%31.72+6.6%20.52-0.4%22.52+11.4%24.02+49.9%29.77+109.9%20.61+19.9%20.22+29.1%
Income Tax Payable15.60+459.1%6.22+130.4%17.12+159.4%8.62+147.7%2.792.70-4.6%6.603.48
Other Current Liabilities38.62+48.3%32.89-20.4%31.44+25.3%34.50+12.7%26.04-5.9%41.34+58.9%25.10-27.9%30.62-7.5%
Total Current Liabilities95.28+68.7%75.76+1.1%73.54+37.5%69.54+25.2%56.49+25.8%74.94+69.6%53.50+0.8%55.54+11.5%
Long Term Debt197.41+148.4%198.91+140.5%199.95+147.4%75.98-6.1%79.48-27.9%82.70-41.0%80.83-42.4%80.90-42.4%
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities---9.11-6.1%---9.70
Other Liabilities1.30-15.0%1.33-45.0%1.37-51.6%1.41-56.2%1.53-58.1%2.42-34.6%2.83-24.5%3.22-15.3%
Total Liabilities293.98+113.8%276.00+72.4%274.86+100.4%156.03+4.5%137.50-13.4%160.06-14.9%137.15-30.4%149.36-23.0%
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity438.51+1.7%408.21+2.5%390.32+4.5%477.32+36.8%431.19+85.9%398.32+111.6%373.42+142.9%349.02+158.1%
Total Shareholders Equity438.51+1.7%408.21+2.5%390.32+4.5%477.32+36.8%431.19+85.9%398.32+111.6%373.42+142.9%349.02+158.1%
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity438.51+1.7%408.21+2.5%390.32+4.5%477.32+36.8%431.19+85.9%398.32+111.6%373.42+142.9%349.02+158.1%
Total Liabilities & Stockholders Equity732.49+28.8%684.21+22.5%665.18+30.3%633.35+27.1%568.69+45.6%558.38+48.3%510.57+45.5%498.38+51.4%
Book Value Per Share per share1.97+8.8%1.81+9.0%1.68+7.0%2.01+35.8%1.81+84.7%1.66+104.9%1.57+137.9%1.48+146.7%
Tangible Book Value Per Share per share1.95+8.9%1.79+8.5%1.66+7.1%1.99+36.3%1.79+86.5%1.65+108.9%1.55+138.5%1.46+151.7%
Full-Time Employees people---647-5.5%---685+9.8%
Price to Book Ratio ratio6.734.984.4910.088.8111.6313.4517.48
Return on Assets %28.0427.1928.1325.9743.6744.7048.0147.77
Return on Equity %41.9541.9043.3035.5663.1771.2378.4581.65
Return on Invested Capital %7.846.237.688.927.137.115.9226.03
Quick Ratio ratio3.253.813.933.743.652.783.362.90
Current Ratio ratio6.046.976.956.717.135.336.585.97

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Net Income49.88+36.9%37.82+10.5%45.33+68.5%49.38-55.9%36.43+1.4%34.22+6.7%26.90+51.0%111.90
Depreciation1.79-11.4%1.78-13.6%1.84-6.6%2.05+5.7%2.02+4.1%2.06+0.5%1.97-6.6%1.94-8.1%
Other Funds (Non Cash)6.37-13.5%6.29+0.6%-1.45-130.3%5.56-19.8%7.36+116.5%6.25+104.2%4.78+100.8%6.93-76.5%
Funds from Operations57.32+13.3%45.90+4.0%49.01+32.2%58.16+59.4%50.61+22.7%44.14+18.8%37.08+66.3%36.49+160.8%
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-39.95-16.369.24-22.52-264.1%-37.32-23.00-371.2%-56.7513.72+281.1%
Cash from Operating Activities17.37+30.7%29.54+39.7%58.2535.64-29.0%13.29-46.9%21.14-53.7%-19.6850.22+185.3%
Capital Expenditures-2.07-2.26-2.60-1.28-14.37-2.53-4.72-2.75
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.005.001.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-2.07-2.262.40-0.28-14.37-2.53-4.72-2.75
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock-25.05-25.02-1314.6%-129.60-129700.0%-8.47-2025.0%-22.65-498.1%2.06+524.2%0.10-90.3%0.44+4300.0%
Repurchase of Common Pref Stock-25.05-25.05-130.19-8.90-23.040.000.000.00
Sale of Common Pref Stock0.01-97.4%0.04-98.1%0.59+490.0%0.43-2.3%0.39-93.1%2.06+524.2%0.10-90.3%0.44+4300.0%
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.94-0.47124.530.55-3.27-0.450.00-30.82
Change in Long Term Debt-0.94-0.47124.530.55-3.27-0.450.00-30.82
Issuance of Long Term Debt0.00-100.0%0.00-100.0%125.00-0.0172.7830.000.000.00-100.0%
Reduction of Long Term Debt-0.94-0.47-0.470.56-76.05-30.450.00-30.82
Net Financing Active Other Cash Flow-0.78-3.93-5.06-1.20-1.90-1.57-7.23-0.64
Other Financing Activities Uses-0.78-3.93-5.06-1.20-1.90-1.57-7.23-0.64
Cash from Financing Activities-26.77-29.42-58940.0%-10.13-9.12-27.820.05-7.13-31.03
Net Change in Cash-11.46-2.13-111.4%50.5226.25+59.7%-28.9018.66-56.5%-31.5216.44
Free Cash Flow15.3727.28+45.7%55.7134.55-27.2%-1.07-104.5%18.72-57.0%-24.3847.46+189.4%
Price to Free Cash Flow ratio17.0416.5520.04159.8888.0768.8353.5638.18

Revenue breakdown

USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.

Product
Name20242025vs 20242025 share
Total Biological Products, (No Diagnostic Substances) revenue426.45510.17+19.6%100.0%
Total426.45510.17+19.6%100.0%
Region
Name20242025vs 20242025 share
Non-US16.316.11-62.6%1.2%
United States410.15504.07+22.9%98.8%
Total426.45510.17+19.6%100.0%
Segment
Name20242025vs 20242025 share
ADMABio Manufacturing415.95493.14+18.6%96.7%
Plasma Collection Centers10.5117.03+62.1%3.3%
Total426.45510.17+19.6%100.0%

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.50%18.0M212.3M2.68M
2026-10-159.11%19.5M214.3M2.68M
2026-09-309.60%20.6M214.7M2.62M
2026-09-1511.28%24.2M214.7M2.69M
2026-08-3111.12%23.9M214.7M2.86M
2026-08-1410.57%22.7M214.7M3.14M
2026-07-3110.08%21.9M217.4M4.20M
2026-07-1510.67%24.0M225.2M4.94M
2026-06-3010.76%24.2M225.2M5.36M
2026-06-159.45%21.3M225.1M6.99M
2026-05-298.83%19.9M225.2M7.11M
2026-05-158.88%20.0M225.3M7.15M
2026-04-309.22%20.7M224.1M5.95M
2026-04-158.39%19.3M230.3M5.23M
2026-03-319.66%22.2M229.6M4.82M
2026-03-1311.25%25.8M229.6M2.62M
2026-02-278.33%19.1M229.6M2.44M
2026-02-139.17%21.0M229.5M2.40M
2026-01-308.45%19.4M229.9M2.87M
2026-01-158.08%18.6M229.9M3.02M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.0010.2014.207.72-13.000.000.995-0.0180.000
call2.009.1013.306.75-10.000.000.992-0.0190.000
call3.008.2012.209.851823.8%1.000.000.983-0.0320.001
call4.007.2011.308.701442.2%0.000.000.978-0.0320.001
call5.006.408.605.42556.8%41.000.000.973-0.0310.001
call6.005.409.306.65783.5%1.000.000.968-0.0310.001
call7.004.406.506.26352.8%14.002.000.961-0.0300.002
call8.003.405.905.26405.0%29.002.000.952-0.0290.002
call9.003.504.803.60314.0%1600.000.941-0.0280.002
call10.002.953.503.05188.0%3480.000.866-0.0540.004
call11.001.902.802.50198.5%5,8891070.829-0.0490.005
call12.000.851.751.80136.4%67335.000.764-0.0410.006
call13.000.400.650.6567.2%1,53437.000.596-0.0330.008
call14.000.000.250.1568.4%8481570.323-0.0330.007
call15.000.000.100.0874.9%1,7150.000.141-0.0210.004
call16.000.000.250.1298.9%3,0130.000.113-0.0230.004
call17.000.000.750.50104.5%2.000.000.061-0.0160.002
call18.000.000.050.08135.3%2080.000.085-0.0250.003
call19.000.000.050.05152.4%13.000.000.078-0.0260.003
call20.000.001.850.03152.1%18.000.000.044-0.0170.002
call21.000.002.050.50168.8%2.000.000.041-0.0180.002
call22.000.000.750.40182.2%1.000.000.039-0.0190.002
call23.000.002.150.00194.7%0.000.000.037-0.0190.002
call24.000.002.150.00206.5%0.000.000.035-0.0200.001
call25.000.000.050.75206.4%11.000.000.034-0.0180.002
put1.000.000.050.00-0.000.00-0.005-0.0160.000
put2.000.000.750.00-0.000.00-0.008-0.0190.000
put3.000.002.150.00604.3%0.000.00-0.017-0.0310.001
put4.000.002.100.12491.8%35.000.00-0.022-0.0310.001
put5.000.002.150.15406.7%11.000.00-0.027-0.0310.001
put6.000.002.150.05337.9%3,0380.00-0.032-0.0300.001
put7.000.000.750.05279.9%1080.00-0.039-0.0290.002
put8.000.000.750.15229.5%1,1740.00-0.048-0.0280.002
put9.000.000.100.05184.4%73.001.00-0.059-0.0270.002
put10.000.000.750.04199.9%1,4830.00-0.134-0.0530.004
put11.000.000.650.38151.7%56.000.00-0.171-0.0470.005
put12.000.000.750.13104.5%56.000.00-0.236-0.0400.006
put13.000.200.400.7867.3%1840.00-0.404-0.0320.008
put14.000.601.151.0089.9%79.001.00-0.677-0.0310.007
put15.000.053.707.00335.8%0.000.00-0.859-0.0190.004
put16.000.704.903.36399.0%0.000.00-0.887-0.0220.004
put17.001.705.808.80418.9%0.000.00-0.939-0.0140.002
put18.002.656.800.00448.3%0.000.00-0.947-0.0150.002
put19.003.807.808.90474.9%0.000.00-0.952-0.0150.002
put20.004.708.8011.32499.3%0.000.00-0.956-0.0160.002
put21.005.709.800.00521.8%0.000.00-0.959-0.0160.002
put22.006.7010.8012.50542.6%0.000.00-0.961-0.0170.002
put23.007.7011.8013.50521.5%0.000.00-0.963-0.0170.002
put24.0010.0011.5015.72389.2%0.000.00-0.965-0.0170.001
put25.009.8013.0011.70484.7%0.002.00-0.966-0.0170.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-08-07SCHEDULE 13GSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-284Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-06-028-KCurrent report2026-06-02SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-05-048-KCurrent report2026-05-04SEC
2026-04-29SCHEDULE 13GSEC
2026-04-15ARSAnnual report to security holders. 2025-12-31SEC
2026-04-15DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-15DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-02SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-03-278-KCurrent report2026-03-27SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-174Statement of changes in beneficial ownership of securities2026-03-13SEC
2026-03-174Statement of changes in beneficial ownership of securities2026-03-16SEC
2026-03-10144Filing for proposed sale of securities under Rule 144.SEC
2026-03-104Statement of changes in beneficial ownership of securities2026-03-06SEC
2026-03-104Statement of changes in beneficial ownership of securities2026-03-06SEC
2026-03-09144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11001.76M1
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05250.87K300
2026-040000
2026-03217.42K2476.16K2
2026-0200337.68K1
2026-010000
2025-1200415.59K1
2025-1100336.00K1

Institutional holders

Manager% owned
BlackRock, Inc.16.55%
STATE STREET CORP6.11%
FIRST TRUST ADVISORS LP4.48%
VANGUARD CAPITAL MANAGEMENT LLC4.36%
VANGUARD PORTFOLIO MANAGEMENT LLC4.35%
Rubric Capital Management LP4.03%
Capital Research Global Investors3.91%
GEODE CAPITAL MANAGEMENT, LLC2.64%
Caligan Partners LP2.47%
D. E. Shaw & Co., Inc.2.28%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF6.03%
SMALLCAP World Fund Inc3.68%
First Trust NYSE Arca Biotechnology Index Fund3.38%
State Street(R) SPDR(R) S&P(R) Biotech ETF3.36%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.03%
iShares Russell 2000 ETF2.59%
Small Cap Growth Fund1.45%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
VANGUARD SMALL-CAP INDEX FUND1.09%
Fidelity Small Cap Index Fund1.09%

OakChart. ADMA. Cached 15 minutes. Terms